Literature DB >> 16335864

Efficiency of potent gastric acid inhibition.

Fernando Carballo1.   

Abstract

The evidence regarding the efficiency of potent gastric acid inhibition is exposed after a systematic search and a critical evaluation of its quality, using a specific score. The aim was to review alternative options, in economic terms, especially related with gastro-oesophageal reflux disease. The results show that the superiority of the proton pump inhibitors over the histamine H2 receptor antagonist is clear in moderate and severe oesophagitis and in patients with persistent or severe symptoms. This evidence is clearly related with the intensity of the gastric inhibition. An associated benefit is the improvement of the quality of life obtained with this potent gastric acid inhibition profile.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16335864     DOI： 10.2165/00003495-200565001-00014

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  26 in total

1.  Health economics of gastroesophageal reflux disease.

Authors:  D Sadowski; M Champion; R Goeree; D Leddin; N Otten; G Morris; I Beck; T Faloon; R N Fedorak
Journal:  Can J Gastroenterol       Date:  1997-09       Impact factor: 3.522

2.  Medical treatment of gastroesophageal reflux disease in the managed care environment.

Authors:  M B Fennerty
Journal:  Semin Gastrointest Dis       Date:  1997-04

3.  Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months.

Authors:  N J Talley; K Lauritsen; H Tunturi-Hihnala; T Lind; B Moum; C Bang; T Schulz; T M Omland; M Delle; O Junghard
Journal:  Aliment Pharmacol Ther       Date:  2001-03       Impact factor: 8.171

4.  Economic analysis of alternative treatments for persistent gastro-oesophageal reflux disease.

Authors:  A L Hillman
Journal:  Scand J Gastroenterol Suppl       Date:  1994

5.  Determining the cost of gastroesophageal reflux disease: a decision analytic model.

Authors:  S S Holzer; T R Juday; B Joelsson; J A Crawley
Journal:  Am J Manag Care       Date:  1998-10       Impact factor: 2.229

6.  Patient, physician, and payer perceptions and misperceptions of willingness to pay for diagnostic certainty.

Authors:  R A Hirth; B S Bloom; M E Chernew; A M Fendrick
Journal:  Int J Technol Assess Health Care       Date:  2000       Impact factor: 2.188

7.  Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies.

Authors:  Peter Wahlqvist; Ola Junghard; Andy Higgins; Jonathan Green
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

8.  Economic evaluation of long-term management strategies for erosive oesophagitis.

Authors:  R Goeree; B O'Brien; R Hunt; G Blackhouse; A Willan; J Watson
Journal:  Pharmacoeconomics       Date:  1999-12       Impact factor: 4.981

9.  Clinical and fiscal impact of lansoprazole intolerance in veterans with gastro-oesophageal reflux disease.

Authors:  L B Gerson; B N Hatton; R Ryono; W Jones; G Pulliam; R E Sampliner; G Triadafilopoulos; R Fass
Journal:  Aliment Pharmacol Ther       Date:  2000-04       Impact factor: 8.171

10.  Quality of life in patients with upper gastrointestinal symptoms. An improved evaluation of treatment regimens?

Authors:  E Dimenäs; H Glise; B Hallerbäck; H Hernqvist; J Svedlund; I Wiklund
Journal:  Scand J Gastroenterol       Date:  1993-08       Impact factor: 2.423
View more
  1 in total

1.  Structure-based prediction of subtype selectivity of histamine H3 receptor selective antagonists in clinical trials.

Authors:  Soo-Kyung Kim; Peter Fristrup; Ravinder Abrol; William A Goddard
Journal:  J Chem Inf Model       Date:  2011-11-16       Impact factor: 4.956
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.